Adelheid_Cerwenkka.jpg

Prof. Dr. Adelheid Cerwenka

Project C2

Department of Immunobiochemistry

Centrum für Biomedizin und Medizintechnik Mannheim (CBTM)

European Center for Angioscience (ECAS)

Medical Faculty Mannheim, Heidelberg University

​

Adelheid.cerwenka(at)medma.uni-heidelberg.de

Adelheid Cerwenka is head of the Department of Immunobiochemistry at the CBTM and ECAS. She pursued her graduate training at the Institute of Immunology at the University of Vienna. She then moved to the laboratory of Richard Dutton at the University of California and the Trudeau Institute in New York. In the laboratory of Lewis Lanier at the University of California in San Francisco she performed further postdoctoral training. She moved on setting up her own group at the German Cancer Research Center in Heidelberg. Since 2017 she is full professor at the Medical Faculty in Mannheim.

Qualifications and Scientific Curriculum

Diploma in Pharmacy, Institute of Immunology, University of Vienna, Austria

​

PhD, Institute of Immunology, University of Vienna, Austria

​

Postdoctoral Fellow, University of California, San Diego, CA, USA and at the Trudeau Institute, New York, USA

​

Postdoctoral Fellow, DNAX Research Institute and University of California, San Francisco, USA

​

Head of Laboratory, Division of Autoimmune Diseases, Novartis Research Institute, Vienna, Austria

 

Junior Group Leader “Innate Immunity”, German Cancer Research Center, Heidelberg, Germany

 

Full Professor, Medical Faculty Mannheim, Heidelberg University, Germany

1986-1991

1991-1995

1996-1998

1998-2001

2001-2003

2003-2016

since 2017

Selected publications​

​

  1. Ni J, Wang X, Stojanovic A, Zhang Q, Wincher M, Bühler L, Arnold A, Correia MP, Winkler M, Koch PS, Sexl V, Höfer T, Cerwenka A: Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity. Immunity, 52:1075-1087, 2020.

  2. Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski L, Lorenz H, Brors B, Cerwenka A: Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc Natl Acad Sci U S A, pii:201720564, 2018.

  3. Pahl JHW, Koch J, Götz JJ, Arnold A, Reusch U, Gantke T, Rajkovic E, Treder M, Cerwenka A: CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells. Cancer Immunol Res, 6:517-527, 2018.

  4. Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A: Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis, J Hepatol, 68:421-30, 2018.

  5. De Ponti A, Wiechert L, Stojanovic A, Longerich T, Marhenke S, Hogg N, Vogel A, Cerwenka A, Schirmacher P, Hess J, Angel P: Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9. Int J Cancer, 136:2458-63, 2015.

  6. Rölle A, Pollmann J, Ewen E, Halenius A, Hengel H, Cerwenka A: IL-12 producing monocytes and HLA-E drive NKG2C+ NK cell expansion in HCMV infection, J Clin Invest, 124:5305-16, 2014.

  7. Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, Textor S, Cerwenka A: Metalloprotease-mediated shedding of B7-H6, the ligand of the activating receptor NKp30, from tumor cells, Cancer Res, 74:3429-40, 2014.

  8. Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A: CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-g production in response to mature dendritic cells. J Immunol, 192: 4184-91, 2014.

  9. Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A: Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood, 122:684-93, 2013.

  10. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A: Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol, 189:5602-11, 2012.